drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Patient-derived T lymphocytes activated and expanded ex vivo and reinfused to mediate anti-tumor cytotoxicity via TCR recognition of tumor neoantigens.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
T-Lymphocytes, Autologous
drug_category
TCR SELECTED T CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous patient T lymphocytes are activated and expanded ex vivo to enrich neoantigen-specific TCR clones. Upon reinfusion, they recognize patient-specific tumor neoantigens presented on HLA and kill tumor cells via TCR-mediated cytotoxicity (perforin/granzyme and cytokine release). No genetic engineering is involved.
drug_name
Autologous T cells (ex vivo expanded)
nct_id_drug_ref
NCT05685004